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Abstract
DEVON ARCH GREGORY: Effects of HSV-1 infection
on disparate cell signaling pathways.
(Under direction of Steven L. Bachenheimer)
Herpes simplex virus (HSV) commandeers cellular machinery in order to replicate.
Two pathways which are utilized by the virus are the NFB pathway and the DNA double
strand break (DSB) response. The NFB pathway is activated in a sustained manner
following infection. This activation leads to a suppression of apoptosis in certain cell types
and may also assist in viral gene expression. The most common route of activation for NFB
is through the IKK complex and IB. This dissertation examines the NFB pathway
upstream of IB, characterizing the role of IKK and IKK, the two kinase subunits of the
IKK complex. Both were found to be necessary for NFB activation, though at different
junctions in the pathway. Potential upstream effectors of the IKK complex are also
characterized. PKR, NIK and Tak1 are kinases that activate the IKK complex following
various normal cellular stimuli. None play a role in activation following HSV infection
however, suggesting a unique method of activation by HSV.
The cellular DSB response normally recognizes breaks in cellular DNA in order to
repair the damage and initiate cell cycle arrest or apoptosis to maintain the integrity of the
cell and organism. This dissertation examines the machinery involved in the initial detection
and signaling of the DSB response following HSV infection. HSV activates the DSB
response dependent upon viral DNA replication. Though downstream signaling in the
pathway is not essential for viral replication, it does contribute to the efficacy of replication.
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Curiously, Mre11 was seen to be lost following infection. Mre11 is a component of the
MRN complex which initially detects DSBs. Its loss suggests that the DSB response is
inhibited and so the mechanism for its loss was pursued. Mre11 loss was not dependent upon
ICP0, nor the activities of the proteasome or lysosome. Viral DNA replication was required
for Mre11 loss, though not late gene expression. Mre11 loss was observed following
activation of the DSB response with camptothecin, suggesting that its loss following
infection is a result of an endogenous cellular mechanism.
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INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is estimated by the CDC to infect up to 90% of
the US population. It is closely related to herpes simplex virus type 2, sharing a homologous
genome with 40% sequence identity. Normally, HSV-1 causes oral fever blisters or cold
sores, while HSV-2 is associated with genital lesions; however, the viruses are capable of
infecting other sites and producing other pathologies. Most common of these are keratitis
from ocular infections that can lead to blindness and herpetic whitlow from infection of one’s
hands or fingers, which is common among health care professionals. The most severe
pathologies occur when HSV enters the central nervous system, causing encephalitis that can
result in death, and when HSV is contracted by neonates.
Both virus types are spread through direct or indirect contact. The virus will usually
initiate a primary infection at the sight of contact, possibly dependent upon pre-existing
breaches in the skin, creating a viral lesion. The propagating virus will infect enervating
neurons, travel through the axon to the cell body by retrograde transport, and become
dormant in the ganglia after the host’s immune system has cleared the initial infection. The
virus will remain in the neurons for as long as it lives, which can be the life of the host.
Periodically, the virus can become active in the neuron, often due to various stresses, and by
antegrade axonal transport, spread back to the area of the initial infection. These
2reoccurrences are normally mild in comparison to the initial infection and are sometimes
even asymptomatic.
Currently there are effective drugs to control HSV, both for initial infection and
recurrences; however, there is no method to remove latent virus and resistances to these
drugs can develop. There are a number of vaccines against HSV and more in development,
however to date none are efficacious enough to be practical. Obviously, by studying the
mechanisms of infection of HSV, we hope to develop additional treatments and perhaps
eventually even a cure. Better understanding viral infection can also help us better
understand the workings of the host as well as help us in developing tools for research and
treatment of other diseases.
HSV-1 
HSV-1 is one of the eight known human herpesviruses and is the prototypical
alphaherpesvirus. The other two known human alphaherpesviruses are HSV-2 and varicella-
zoster virus. The betaherpesviruses include human cytomegalovirus (HCMV) and human
herpesviruses 6 and 7. The human gammaherpesviruses are Epstein-Barr virus (EBV) and
Kaposi sarcoma-associated herpes virus or human herpes virus 8 (KSHV). HSV-1 has a
linear double stranded DNA genome of roughly 152kb, which encodes over 80 genes. In the
virion, the genome is surrounded by an icosahedral capsid. Surrounding the capsid is the
tegument layer, comprised of many proteins encoded by the virus. The envelope, comprised
of a lipid bilayer embedded with glycoproteins surrounds the tegument and capsid.
On a cellular level, HSV-1 infection begins when envelope glycoproteins facilitate
binding and entry into a host cell. Glycoprotein B (gB) or gC initially interact with heparin
sulfate on the cell surface, followed by gD interaction with coreceptors (77, 135, 143). A
3number of receptors can interact with gD, including the TNF receptor family member
HVEM, immunoglobulin family members HveB (nectin-2), HveC (nectin-1) and HIgB, and
3-O-sulfated heparin sulfate (21, 43, 100, 138). The above has been characterized for cell
surface mediated entry, though HSV can also enter cells through an endocytic route (102).
Regardless, the tegument and nucleocapsid are eventually released into the cytoplasm. The
capsid is then transported via the microtubule network to the nucleus in order to release the
viral DNA through a nuclear pore (122, 139).
Once inside the nucleus, the linear genome is circularized, localized to ND10s and
gene expression is initiated, though not necessarily in that order (122). Viral gene expression
occurs in a temporal cascade, beginning with immediate early (IE) genes, then early (E)
genes and finally late (L) genes following viral DNA replication (also known as ,  and 
genes). Virion associated protein 16 (VP16) and host proteins HCF and Oct1 activate IE
gene transcription via the TAATGARAT sequence found in all IE gene promoters. There are
five IE genes, Infected Cell Proteins (ICPs) 0, 4, 22, 27 and 47. ICP0 is a promiscuous
transactivator, important for enhancing viral gene expression and accelerating infection
progression (14, 32, 33). ICP0 also possesses E3 ubiquitin ligase activity and is capable of
ubiquitinating many proteins, including PML, p53, DNA-PKcs and IkB (12, 26, 35, 80,
106). In the case of DNA-PKcs and PML, ubiquitination by ICP0 leads to proteasomal
degradation in vivo. ICP4 is necessary for expression of E and L viral genes by stabilizing
general transcription factors on viral promoters. ICP4 down regulates IE gene expression as
well (25). ICP22 has also been implicated in upregulating viral gene transcription, though it
does not have transactivation activity itself (115, 121). ICP27 regulates gene expression post
transcriptionaly through its interactions with polyadenylation and splicing machinery (53,
4112, 120). ICP27 also activates several cellular signal transduction pathways (54, 96, 109).
ICP47 is the only IE gene that does not function to regulate gene expression. Instead it
blocks peptide loading onto transporter of antigen presentation (TAP) complexes in order to
promote immune evasion (39, 59).
Dependent upon IE gene products, expression of the second class of HSV-1 genes
occurs. These E genes encode components of the viral DNA replication machinery,
including the viral DNA polymerase UL30, single stranded DNA binding protein ICP8 (also
called UL29), the processivity factor UL42, origin-binding protein UL9 and the helicase-
primase complex consisting of UL5, UL8 and UL52. These localize to so-called
prereplicative sites, likely previous ND10 sites, where viral DNA replication is thought to be
initiated. Active DNA replication expands these sites, forming replication compartments that
fill most of the host nucleus. HSV DNA replication initiates dependent upon UL9, where bi-
directional theta replication occurs. At some point however, DNA replication is thought to
switch to a rolling circle and/or recombination dependent mechanism (165). The resultant
viral DNA is a complex multi-branched concatameric structure.
Following initiation of DNA replication the L genes are transcribed. This class is
further divided into leaky late genes that do not require viral DNA replication for expression
and true late genes that absolutely require DNA replication for expression. This
classification is not entirely accurate however, as all late genes lie on a continuum for the
requirement of viral DNA replication (144). Late gene products include the structural
components of the virion and machinery necessary for assembling the virion and exporting it
out of the cell.
5During the course of infection, the host cell has its normal functions modified so that
all available resources become available for the virus to replicate itself. ICP27 and the
tegument protein vhs (virion host shutoff) inhibit host cell translation by preventing mRNA
maturation and by degrading pre-existing mRNA respectively (24, 128). Cellular DNA is
condensed and marginalized and cell cycle is halted at G1/S and G2/M (29, 88, 103, 140).
HSV-1 also counters the cell's innate defenses against viruses. ICP27 prevents apoptosis
through its activation of NFB and possibly through other mechanisms (49, 50). ICP34.5
counters transcriptional suppression by PKR by directing dephosphorylation of eIF2 (20).
Ultimately, viral replication depletes the cell of metabolic resources and causes necrosis.
When HSV-1 infects a neuron, it does not proceed along the lytic course described above,
but rather becomes latent. The exact mechanisms by which this manner of infection occurs
are not fully understood. It is known that some limited amount of replication occurs within
the neuron before the virus becomes silent, meaning that gene expression is curtailed.
Though the initial trigger for this switch is unknown, it is thought to be maintained by a
chronic immune response (71). Because neurons are generally not turned over, latency
persists for the life of the infected individual. The virus may reactivate periodically, often
due to stress, possibly because of decreased immune activity during such times. When
reactivation occurs, virions are transported antrograde where they infect cells proximal to the
original sight of infection. Though the reactivated neuron eventually dies, HSV is
maintained in the host till death because not every latently infected neuron reactivates at once
and reactivation can lead to infection of previously virus free neurons.
6NFB
All human pathogens must contend with their host's immune response, and HSV is no
exception. Central to many of these barriers is nuclear factor Kappa B (NFB). NFB is a
family of transcription factors that can positively and negatively regulate a number of genes
involved in proliferation, apoptosis, inflammation, stress responses, innate and adaptive
immune response, oncogenesis and development, all of which contain B elements, to which
NFB binds, (44, 67, 105, 107). The exact function of NFB when activated is highly
dependent upon the state of other signaling pathways, other transcription factors and the
stimuli responsible for activating NFB (57, 113). The interplay between all these cellular
components can determine whether apoptosis or an inflammatory response is initiated.
There are five different NFB subunits that can dimerize to form a functional
transcriptional factor; p65 (relA), RelB, c-Rel, p50 and p52. All the subunits contain a Rel-
homology domain which is necessary for DNA binding and dimer formation. Both p50 and
p52 can form homodimers or dimerize with any other subunit. The other three subunits only
dimerize with p50 or p52 and also contain transactivation domains. Dimers of p50 and p52
can still activate gene expression by interaction with the transcriptional co-activator BCL-3
(10).
Activation of the NFB pathway normally results from signaling from cell surface or
intracellular receptors triggered by cytokines or molecules containing pathogen associated
molecular patterns, but various cellular stresses, such as DNA damage, can also lead to
activation. TNF, IL1 and LPS are amongst the best known activators of NFB, though
there are numerous others, some likely yet to be discovered. As there are a number of
extracellular and intracellular signals that lead to NFB activation, there are many different
7signaling cascades that can trigger NFB activation. Normally however, these signaling
pathways converge at a signaling bottleneck, the IKK complex. After this point, NFB
activation again is somewhat varied, though there is one pathway that is most frequently
observed across many cell types, known as the classical or canonical pathway. Because of its
relevance here and the complexity of the many other routes of activation, it will be the only
one described.
The classical pathway signals through the IKK complex consisting of inhibitor of B
kinase  (IKK), IKK and IKK. IKK and IKK are kinases that target NFB subunits
and a class of regulator proteins known as Inhibitor of B (IB). There are 5 IB proteins;
IB, IB, IB, IB and BCL-3. In the classical pathway, IB binds to a p65/p50
heterodimer and masks p65’s nuclear localization sequence. Phosphorylation of IB by
IKK leads to its poly-ubiquitination and proteasome dependent degradation. Once released
from IB NFB localizes to the nucleus. It is further regulated by post-translational
modifications. Phosphorylation of serine 276 results in a switch of p65’s interaction from
histone deacetylases such as HDAC to histone acetyl-transferases such as CBP/p300,
promoting gene transactivation. Serine 529 and 536 also play a role in promoting
transactivation, while serine 311 is important for DNA binding. Acetylation at a number of
sites also promotes NFB transactivation (reviewed in (57, 113, 132, 161)).
Upstream of IKK in the classical pathway are a number of signaling paths. The most
commonly studied is the path from TNF (reviewed in (57)). TNF is a cytokine that signals
through its receptor TNFR1. When TNFR1 binds TNF, it aggregates and binds adapter
molecules to activate various signaling pathways. For NFB activation, TRADD, RIP and
Traf2 or 5 are the necessary adapters. Once these adapters have bound TNFR1, they recruit
8the IKK complex and TAK1, which leads to activation of both (136). Once IKK has been
activated, NFB signaling proceeds as described above.
NFB and viruses
NFB is very significant for microbial pathogens. Its role in the immune response is a
important hurdle to overcome, and many viruses and bacteria have developed mechanisms to
interfere with NFB activation (46, 62). NFB activation can also serve to benefit viruses
however, and several viruses activate and exploit the pathway (61). Perhaps the most well
known case is HIV-1. HIV-1 contains B elements in its LTR that, in conjunction with other
transcription elements, are necessary for efficient transcription. HIV-1 can cause NFB
activation through several mechanisms. HIV-1 binding to its receptor, CD4, which can
signal to the NFB pathway when activated, causes induction of NFB. HIV-1 Tat induces
NFB activation through engagement of cellular signaling cascades involving p56ick, while
Vpr and Nef induce IL-8 and IL-2 signaling respectively, causing NFB activation. And
finally, activation of the immune response by HIV-1 also results in NFB activation.
Many other viruses also contain NFB binding sites, of most relevance here are the
herpes viruses. Both EBV and KSHV have NFB binding sites in the promoters of their
major oncogenic proteins, LMP1 and K1 respectively, though it is unclear what role NFB
plays in transcriptional control in vivo (7). The HCMV IE1 promoter contains 4 NFB sites,
which may be important for(127) reactivation from latency as well as normal lytic expresion
(6, 127). HSV also has NFB sites in the promoters of ICP0 and VP16, which for the ICP0
gene are capable of binding NFB (4, 123). Activation of NFB in all these viruses has been
shown to benefit replication (17, 52, 61, 69, 70, 109, 118, 127, 156).
9HSV’s ability to activate NFB was first observed in studies looking at HSV-1
activation of HIV provirus (47). The activation is primarily of p65/p50 heterodimers
necessary for efficient HSV replication (109, 130). More recently, two phases of NFB
activation have been reported. The initial activation is likely triggered by HSV engagement
of receptors capable of signaling to NFB, and is transient in duration (4, 98, 155). The
second activation of NFB is dependent upon IB turnover and is sustained for the length of
infection (109). Though ICP4 (vi13) and ICP27 (n59r) deficient mutants are both impaired
for NFB DNA biding, n12, a ICP4 mutant, shows only partial impairment of IB loss while
d27-1, a ICP27 null mutant is unable to cause IB loss (55, 109). Also, an HSV mutant
expressing only ICP27, ICP22 and ICP47 (d100) causes IB degradation by 24 hpi. ICP27’s
activity that leads to NFB activation was mapped to a domain within residues 12 to 63 and
is also in part dependent upon activation of JNK and p38 signaling pathways, as
pharmacological inhibitors of JNK and p38 also reduce IB loss (55).
As mentioned above, ICP0 and other genes contain B sites in their promoters (123).
For ICP0, NFB has been shown to bind and contribute to transactivation (4). What role
NFB might play in gene regulation for other HSV genes is not known. NFB does however
appear to inhibit apoptosis in some cell types. HSV infection of HEp-2 cells that either
express a dominant negative IB, or are treated with a pharmacological inhibitor of IB
degradation, induces apoptosis (49, 50). Other reports have suggested that NFB does not
actually play a role in inhibiting apoptosis. SK-N-SH cells infected with R5104, a HSV
mutant that aberrantly expresses Us11 at the immediate early stage, fails to cause NFB
activation, but also does not cause apoptosis (147). Mouse embryo fibroblasts (MEFs)
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knocked out for p65, p50 or both also do not undergo apoptosis following wt or d120 (a ICP4
deleted mutant) infection, while the latter causes apoptosis in other cell types (148).
The conclusions from the latter experiments are problematic however. R5104 varies
from wildtype HSV by several changes, and it is unclear how these may effect both the
induction and inhibition of apoptosis separate from NFB activity (16). It is difficult to
interpret the results from the MEFs because while they do not undergo apoptosis following
wt infection, as one might expect if NFB was necessary to prevent apoptosis following
infection, they also do not undergo apoptosis following d120 infection. Infection with d120
does not activate NFB and thus should cause apoptosis regardless of NFB's presence in the
cell. This result suggests that these cell lines have gained a function that either prevents
induction of apoptosis due to HSV infection or inhibits apoptosis independent of NFB.
Because these cell lines are sensitive to TNF or sorbitol apoptosis induction, the latter is
unlikely (148).
Currently, the pathways leading to NFB activation are poorly understood and have
been part of my dissertation research. IKK is activated following infection, and treatment of
infected cells with prostaglandin A1 (PGA1) inhibited both IKK and NFB activation (3). In
this study, PGA1 also inhibited immediate early gene expression, so it was unclear from
these results whether IKK is necessary for NFB activation during infection, though it would
be expected to be. My own work confirmed IKK to be necessary for NFB activation by
HSV and expanded our knowledge for the role of each kinase subunit using MEFs knocked
out for one or both of the kinase subunits (50). There are many potential upstream activators
of IKK, and which one might target IKK following HSV infection. Taddeo et al reported
that PKR is upstream of NFB activation. However my results do not bear this out (50, 147).
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The reason for this discrepancy is unclear. I have also characterized two other potential
upstream kinases, TAK1 and NIK, and shown that they are not relevant for HSV activation
of NFB.
Double Strand Break Response
Many types of DNA damage threaten the genomic integrity of a cell. DNA DSBs are
one of the more dangerous types of damage, resulting from ionizing radiation, genotoxic
chemicals, collapsed replication forks (often due to pre-existing damage in the DNA) and
purposeful DNA cleavage for cellular processes, such as V(D)J recombination. If not
repaired promptly and properly, DSBs can result in loss of large portions of chromosomes
and in translocations and large deletions, potentially causing cell death or deregulation, a
worse fate for the organism if cancer results. To avoid these fates, cells have a complex
system in place to quickly detect DSB and respond to them.
Primary in the response to DSBs is the MRN complex, comprised of Mre11, Rad50
and Nbs1 (22, 63, 78). The MRN complex is responsible for recognizing free DNA ends and
tethering the two broken ends together. The MRN complex also possesses nuclease and
helicase activity that process the ends for repair (110, 111, 157). Subsequent to finding the
DSB and binding, MRN interacts with ATM, causing ATM to become active through
autophosphorylation (9, 15, 79, 160). At this point, signal amplification occurs as ATM
phosphorylates a number of components to further repair and alert the cell to the occurrence
of the break. At or near the site of the break and to a newly activated ATM are two of its
targets, NBS1 and H2A.X (13, 86). H2A.X is a variant of histone H2A, and its
phosphorylation allows it to act as a landing pad for MDC1 (170). MDC1 acts as a scaffold
to the MRN complex via interaction with NBS1 and aids in further ATM activity (91, 99).
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ATM also phosphorylates 53BP1 and BRCA1, which act as additional scaffolding and are
important to recruit and aid in activation of some of ATM’s other targets, such as p53 and the
Chk proteins (38, 41, 94, 99).
In mammalian cells, repair normally occurs via non-homologous end joining (NHEJ),
resulting in two broken DNA ends being ligated together regardless of sequence. This non-
specificity can lead to small deletions or insertions. For this process of repair, the
heterodimeric Ku (Ku70/86) recognizes the DNA ends while the actual rejoining of the ends
occurs via the Xrcc4/LigaseIV complex aided by pol µ (63, 92, 108, 158). Though we know
these components are necessary for NHEJ, the full details of their interactions are as yet
unknown. Another protein that is sometimes involved in NHEJ is the catalytic subunit of
DNA dependent protein kinase (DNA-PKcs). DNA-PKcs seems to be necessary for a subset
of NHEJ that does not involve the MRN complex.
The other common mechanism by which DSBs are repaired is homologous
recombination (HR). This mechanism has been primarily studied in fungi, where it is the
primary method of repairing DSB. However, the mechanisms of HR appear to be highly
conserved throughout all eukaryotes. HR more accurately repairs DSB and requires a
homologous template to the broken duplex, i.e. a sister cromatid. The Rad52 epistasis group
(comprised of the MRN complex, RPA, Rad51, Rad52, Rad54, Xrcc2 and Xrcc3) is
responsible for the mechanisms of HR. HR has been thoroughly studied and reviewed (142,
167, 168). In simplified summary, a single strand from the broken DNA is bound up by RPA
and then Rad54 facilitates loading of Rad52 and Rad51, which form a filament around the
single strand (ss) DNA and cause it to invade the double strand (ds) DNA of a homologous
duplex. This invasion causes the displacement of one of the intact strands, which can then
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form a duplex with the complimentary strand from the broken DNA, all promoted by Rad51
and Rad54. Strands exchange between the homologous DNA occurs and the crossed DNA
strands are resolved by being cut and rejoined to the appropriate new dsDNA molecule.
In addition to facilitating repair, ATM also activates cell cycle checkpoints and in
extreme cases, apoptosis. ATM phosphorylates ATR, Chk2, Chk1 and p53, all of which can
inhibit cell cycle progression (23, 66, 68). ATR can also be activated through interactions
with the MRN complex and is a potent activator of Chk1 (94). Chk1 and Chk2 target Cdc25
proteins to inactivate them (42). Normally Cdc25 proteins serve to positively regulate Cdk
activity, necessary for cell cycle progression, by removing inhibitory phosphorylations (56,
169). p53 can also inactivate Cdk proteins through its transcriptional regulation of p21,
which directly binds to Cdk/cyclin complexes and prevents ATP binding (124). Apoptosis
can also be induced by p53, though this requires either additional signals or differential
activation as this only occurs in cases of irreparable damage (90).
Viruses and the DNA DSB response
Many previous reports have found interactions between viruses and host cell DNA
DSB response machinery. In some instances, cellular DSB machinery is detrimental to a
virus, and as such the virus in question has mechanisms to prevent the actions of the cellular
response machinery. In other cases, viruses are able to harness the cellular machinery for
their own advantage. Whether the cellular machinery is harmful or beneficial for a virus
depends on the life cycle of the virus, and in some instances the machinery can be both.
SV40 is a circular dsDNA virus with strong oncogenic properties. The large T
antigen of SV40 is a key component for the oncogenic properties of SV40. One transforming
mechanism of SV40 large T antigen is to directly bind p53 and prevent its transcriptional
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activity that is important in the DNA damage response (76). More recent reports have
elucidated a role for SV40 large T antigen in hindering the initial stages of the DNA damage
response. Study of cardiomyocytes transformed with SV40 large T antigen found that Mre11
co-immunoprecipitated with SV40 large T antigen and that transformed cell lines had greatly
reduced Mre11 protein, though not mRNA. Nbs1 and Rad50 in contrast seemed not to have
decreased protein levels (28). In fibroblasts, the presence of SV40 large T antigen was noted
to cause a decrease in Mre11 foci formation following IR treatment (166). Unfortunately,
none of these studies ventured into actual SV40 infection, so the benefit these actions of large
T antigen have on SV40 replication remain in the realm of speculation.
One study of interesting note did find a role for SV40 large T antigen in the context
of infection. Wu and colleagues discovered that SV40 large T antigen directly binds to
Nbs1. This binding prevents Nbs1, and presumably the entire MRN complex, from
preventing refiring of origins of replication that lead to erroneous duplication during S phase.
SV40 relies entirely on host DNA replication machinery to duplicate its genome, so loss of
replication control allows the SV40 genome to undergo exponential replication (119, 129,
173). Though it is unknown whether this function of the MRN complex is tied to a DNA
damage response, these results show an interesting interaction between a virus and DNA
damage response machinery.
Like HSV, adenovirus has a linear dsDNA genome. Adenovirus E1B-55K binds and
hinders p53 transcriptional activity and in conjunction with E4orf6 causes p53 to be degraded
(146). Adenovirus control of p53 allows suppression of apoptosis induced by the virus. It
also has two means to inactivate the MRN complex. Late in infection Mre11 and possibly all
three components of the MRN complex are degraded dependent upon either E4orf3 or
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E1B55K/E4orf6 (31). This late loss of the MRN complex prevents detection of DSB breaks
and activation of ATM. For the virus, this failure of the DNA damage response allows its
linear progeny genomes to escape concatamerization, which would prevent their packaging.
Earlier in infection however, E4orf3 binds the MRN complex and sequesters it to foci
throughout the nucleus. This activity of E4orf3 is necessary for viral DNA replication to
occur (73).
Recently Kudoh and colleagues characterized components of the DNA damage
response during the EBV lytic cycle (95). They found that ATM was activated and
phosphorylated Chk2, p53, H2AX and Nbs1. They also observed that activated ATM and
MRN complex colocalized with replicating EBV DNA. Interestingly, EBV BZLF-1, a major
transcriptional transactivator, counters the down stream effects of cell cycle checkpoint
induction by ATM by binding and inhibiting p53 and by activating promoters of the cell
cycle, such as E2F-1, cyclin E and Cdc25A (80, 106). These finding indicate that activation
of the cell cycle checkpoint by the damage response would be detrimental to EBV
replication. However, whether other components such as the MRN complex have any affect
on EBV replication is not yet known.
The first reported effect of HSV-1 on the DSB response was the observation that
HSV-1 caused the degradation of DNA-PKcs via ICP0 (51). This loss is thought to hinder
NHEJ, which could potentially act upon viral DNA (84, 137, 154, 162, 164). Several recent
reports have also established a link between viral DNA replication and components of the
DSB response. RPA, DNA-PKcs, Rad51, Mre11, Nbs1, ATM, Rad50 and Ku were seen via
indirect immunofluorescence microscopy (IF) to localize to replication compartments, and all
but Ku and DNA-PKcs also localized to prereplicative sites (154). HSV-1 ssDNA binding
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protein, ICP8, which is present at sites of DNA replication, has also been shown to interact
with DNA-PKcs, Rad50, Ku, Mre11, RPA and BRCA1 (84, 137, 164). Similar to EBV,
HSV-1 also causes activation of many DSB response factors, in this case Nbs1, RPA, ATM,
Chk2 and 53BP1 (85). These activation events appear to occur by the MRN complex’s
activation of ATM, independent of active viral DNA replication. The importance of this
activation is underlined by a report by Lilley et al. that demonstrates the inability of virus to
replicate in cells deficient for the MRN complex or ATM (137). The importance of ATM
has been disputed however, as Shirata et al. reported that while cells from individual with AT
or NBS are defective in supporting viral infection, specific knockdown of ATM with siRNA
had no effect on viral replication (154). Interestingly, cells deficient in Ku actually facilitate
viral replication better than wild type (wt) cells (163). In contrast, HSV inhibits ATR, and
thus Chk1, activation (165).
HR is induced by HSV-1 infection as evidenced by recombination during heterotypic
coinfection or isomerization of HSV-1’s genome during normal infection. HR may also play
an important role in viral DNA replication by recovering stalled replication forks (81, 82).
Many of the DSB response factors are important components in the HR machinery and thus
their importance in HSV-1 replication might be explained. Thus, in one aspect, HSV-1 uses
the DSB response machinery to aid in its own replication. However in the case of DNA-
PKcs, Ku and perhaps NHEJ in general, HSV-1 seems to antagonize or be antagonized by
the DSB response machinery. NHEJ might also be the mechanism of genome circularization
during the establishment of latency in neurons. With this paradox it is important to
understand the stages of HSV-1’s life cycle in which the DSB response interacts with the
virus. Currently, evidence suggests a positive role for the DSB response in DNA replication.
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As of yet, we do not know if the DSB response machinery might have an effect on late
events, such as processing and packaging of replicated DNA.
Materials and Methods
Cells: Spontaneously immortalized mouse embryo fibroblasts (MEFs) derived from
normal mice or mice with targeted deletions in IKK , or IKK (172) were obtained form Tal
Kafri (UNC-Chapel Hill). MEFs from normal mice or mice with a targeted deletion of the
double-stranded RNA-activated protein kinase PKR (37) were obtained from Bryan Williams
(Cleveland Clinic). Diploid human embryonic lung fibroblasts (HELs) and HeLa cells were
obtained from ATCC. The above cells were maintained in Dulbecco’s Minimal Essential
Medium (DMEM) supplemented with 10% fetal bovine calf serum, 100U/ml penicillin, 1%
streptomycin, and 1% L-glutamine. Hep2 cells obtained from ATCC were maintained in
Minimal Essential Medium supplemented as for DMEM. CV-1 cells were obtained from
Saul Silverstein (Saul Silverstein) and grown in DMEM supplemented with 5% newborn calf
serum, 100U/ml penicillin, 1% streptomycin, and 1% L-glutamine. Telomerase
immortalized human foreskin keratinocytes (HFKs) were a gift from Shannon Kenney
(University of Wisconsin-Madison) and Nancy Raab-Traub (UNC-Chapel Hill) with
permission from A. J. Klingelhutz who derived the cell line as previously described (104).
HFKs were maintained in Keratinocyte-SFM from Gibco supplemented with EGF and
bovine pituitary extract.
Viruses: HSV-1 strains KOS1.1 and 17+ were used as the wildtype (wt) virus strains.
The following mutants were used: ICP8 mutant d301 (David Knipe, Harvard Univ.); UL30
(polymerase) mutant HP66 (Donald Coen, Harvard Univ.); ICP0 null mutants 7134, d22 and
d99 (Priscilla Schaffer, Harvard Univ.); ICP4 mutant n12 (Neal DeLuca, Univ. of
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Pittsburgh); UL17 mutant UL17 (Joel Baines, Cornel Univ.); UL25 and UL28 mutants
kUL25 and GCB (Fred Homa, Univ. of Pittsburgh); UL15, UL32 and UL6 mutants hr81-1, 
hr64 and hr74 (Sandy Weller, Univ. of Conneticut) and UL26 mutants dZ and H61E
(Prashant Desai, John Hopkins Univ.).
Antibodies: Rabbit polyclonal antibodies against IKK (H-470, sc-7607), IKK (H-
744, sc-7218), IB- (C-21, sc-371), PARP (H-250, sc-7150) were purchased from Santa
Cruz. Polyclonal antibody against p65 (100-4165) was purchased from Rockland.
Monoclonal antibodies against Rad50 (13B3) and Mre11 (12D7) and polyclonal antibody
against Mre11 (GTX30294) were purchased from Genetex, Inc. Monoclonal antibody
against Nbs1 (100-222) and polyclonal antibodies against phospho-Nbs1 (100-284) and
phospho-ATM (100-307A2) were obtained from Novus Biologicals. Monoclonal antibody
DNA-PKcs (05-423) was purchased from Upstate. Monoclonal antibody against ICP0
(H1A027-100) was purchased from Virusys. Monoclonal antibodies against ICP4 (1101)
and ICP27 (H1113) were purchased from Rumbaugh-Goodwin Institute. Polyclonal
antibody against ICP8 (3-83) was a gift from David Knipe. Polyclonal antibody against gC
(R47) was a gift from Gary Cohen and Roselyn Eisenberg. Polyclonal antibody against
VP16 was purchased from Clontech. Goat anti-rabbit and anti-mouse HRP-conjugated
secondary antibodies were purchased from Amersham Biosciences
Infection and preparation of extracts: Near confluent or confluent monolayers seeded
one to two days previously were inoculated with virus at the indicated multiplicity of
infection (MOI) calculated based on titers corrected for the host cell lines (1 HEL/HFK pfu ~
4 Vero pfu). Thirty minutes to one hour following inoculation, cells were overlayed with
spent media or spent media containing 400 µg/mL phosphonoacedic acid (PAA (an inhibitor
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of herpesvirus DNA polymerase)), 10 µg/mL cycloheximide, 5 µg/mL Actinomycin D, 5mM
Caffeine, 10µM KU-55933 or, NH4Cl or MG132 (Sigma) at the indicated concentrations.
Monolayers were harvested by washing with cold PBS and then scraping directly into 1X
SDS sample buffer [3.85mM Tris-base (pH 6.8), 9.1% -mercaptoethanol, 1.82% SDS, 4.6%
glycerol, and 0.023% bromophenol blue (in 100% EtOH)] and boiling for 5’. In the case of
HELs, media from monolayers was collected and the monolayers were treated with trypsin
until the cells detached. The cells were then suspended in PBS, combined with the
previously collected media and were spun down and washed once with PBS before addition
of 1X SDS sample buffer and boiling as above. Fractionated cytoplasmic and nuclear
extracts were prepared as described previously (60, 104, 109). Briefly, cells were collected
by trypsinization, spun through a cushion of bovine calf serum, washed twice in PBS,
resuspended in 3 packed cell volumes of CE buffer (10 mM HEPES, pH 7.8, 1 mM EDTA,
60mM KCl, 1 mM PMSF, 0.1% NP-40, 25% glycerol, 0.4mM NaF, 0.4 mM Na3VO4, 10µM
pepstatin, and Complete Protease Inhibitor Cocktail [Roche]) and incubated on ice for 10’.
Following a 10 sec spin in a bench-top microcentrifuge, the supernatant was collected and
the nuclear pellet resuspended in CW buffer (CE buffer without NP40 or glycerol), and
repelleted. Nuclei were resuspended in 2 packed cell volumes of NE buffer (20mM Tris-HCl,
pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 25% glycerol, and
phosphatase and protease inhibitors as described above). After incubation on ice for 10’,
nuclei were pelleted at 60,000 rpm at 4oC for 20’ in a Beckman TLA100.3 rotor and the
nuclear supernatant recovered.
Western Blotting: Cell or protein equivalents of samples were separated by SDS-
PAGE and transferred to PolyScreen polyvinylidene difluoride membranes (Perkin-Elmer
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Life Sciences). Ponceau S (Sigma) was used to visualize total protein and insure no
discrepancies in protein equivalences. Membranes were blocked in 5% milk in TBST
(150mM NaCl, 20mM Tris [pH 7.6], 0.05% Tween 20) then washed and probed with
appropriate primary antibodies, followed by further washing and probing with the
appropriate secondary antibody, all in TBST. After final washing in TBST, signal was
detected using Perkin-Elmer Western Lightening substrate. Multiple exposures were made
on Kodak BMR film to insure the linear range was obtained. Images were scanned and
processed using Adobe Photoshop.
Electrophoretic mobility shift assay (EMSA): Preparation of nuclear extracts and
mobility shift assays for NFB were performed as described previously (50). Nuclear extract
were incubated with a radiolabeled probe containing a B-binding site
TGGGGATTCCCCA in buffer containing 10mM Tris-HCl (pH 7.9), 50mM NaCl, 0.5mM
EDTA, 10% glycerol, 1 mM DTT, and 2µg poly (dIdC)·(poly dIdC). Following 20’
incubation at room temperature, aliquots were fractionated at 4oC on non-denaturing 4%
polyacrylamide gels prepared in 0.25X TBE [1X TBE is 10mM Tris base (pH 8.3), 9mM
boric acid, and 2mM EDTA]. Gels were then placed on 3MM paper, dried under vacuum and
heat, and exposed to BMR film at –70oC.
Plaque assay: Virus was titered as described previously (50). Monolayers of cells in
60mm or 100mm dishes were infected with HSV at a MOI of 5. Cells and medium were
harvested at various times pi. and subjected to 4 freeze/thaw cycles in an ethanol and dry ice
bath then 37 oC water bath. Serial 10-fold dilutions of the lysates were assayed in triplicate
on monolayers of Vero or CV-1 cells in 12 well dishes. After 1h, monolayers were covered
with DMEM-H containing 2% CS and 0.3% methylcellulose. After 3d incubation at 37oC,
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medium was aspirated from the wells and plaques stained with 0.8% crystal violet in 50%
ethanol.
Immunofluorescence: Cells were seeded on glass coverslips and allowed to grow
until confluent. The monolayers were infected at low multiplicity (MOI of .1 or .01). At the
indicated times, cells were washed with PBS, then fixed with 5% paraformaldehyde in PBS
for 10 minutes followed by permeabilization with 1% Triton X-100 in PBS. The cells were
then incubated in blocking buffer (2.5% normal goat serum, 2.5% normal horse serum and
1% gelatin in PBS) for at least 30 minutes, probed with the indicated primary antibody, and
then washed and probed with either Texas red conjugated anti-rabbit or FITC conjugated
anti-mouse antibody (Santa Cruz), all in blocking buffer. Primary antibodies were omitted
for control cells. Following final washing with PBS, the coverslips were mounted and
allowed to set before visualization with an Olympus FV500 confocal laser scanning
microscope.
Real time PCR: Cell monolayers were infected at an MOI of 5 as above and then
harvested using Promega Wizard SV Genomic DNA Purification System to isolate cellular
and viral DNA. Primers against c-Myc (TCAAGAGGTGCCACGTCTCC,
TCTTGGCAGCAGGATAGTCCTT) and UL19 (AAACATCGCTGCCTGGAG,
GGGGCGCTTAAACTGTACG) were designed by Dirk Dittmer. DNA and primers diluted
1:200 were mixed with SyberGreen and run on an ABI prism 7000 for 40 cycles at 95o
denaturing for 30" and 55o annealing for 1'. 7000 systems SDS software was used to collect
cycle data. Fold viral DNA copy was calculated based on dCt of UL19 normalized to the dCt
of c-Myc.
CHAPTER 2
CHARACTERIZATION OF NFB ACTIVATION FOLLOWING HSV INFECTION
[A portion of the results presented here were published in Gregory et al., 2004 (50)]
At the outset of our research presented here, it had long been known that NFB was
activated by HSV infection, but little was known regarding the cause or reason for NFB
activation. A report by Amici et al had recently demonstrated the activation of the IKK
complex following HSV infection by kinase assay of immunoprecipitated IKK complexes
(109). To test whether IKK activity was causing NFB activation following HSV infection,
they used PGA1, a prostaglandin, to inhibit IKK activity and assess for NFB activation by
IB turnover, NFB gel shift activity and NFB reporter activity. In all cases, PGA1
treatment caused loss of IKK activity and failure of NFB activation. They concluded from
this that IKK was behaving normally as part of the canonical NFB pathway,
phosphorylating IB and causing its degradation. They also demonstrated, as have others,
that loss of NFB activation greatly reduced virus yield, concluding it to be a necessary
component of HSV infection (125).
While these are reasonable conclusions, the Amici et al. study suffers from the
standard caveats of using pharmacological inhibitors, namely secondary targets and
cytotoxicity. While a previous report by this group did show that other cellular kinases were
not as sensitive to PGA1, they did not include such controls in their system for HSV (109).
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They did assay for toxicity of PGA1 in their HSV system and claimed no affect. However,
their results do show a marked reduction in ICP4 protein levels, which has been shown to
contribute to NFB activation, as well as a general failure of HSV to create a normal [35S]
methionine-labeled polypeptide profile (159). Due to these results, the contribution of IKK
to NFB activation and HSV infection remained unclear.
To clarify the role of the IKK complex in NFB during HSV infection and the
involvement of its common upstream effectors, we sought to use a genetic approach. We
obtained wild type (wt) mouse embryo fibroblasts (MEFs) or MEFs knocked out for either
IKK or IKK. These cell lines were characterized for their ability to facilitate HSV
infection and NFB activation. Our results indicated that IKK is indeed necessary for NFB
activation, with each kinase subunit uniquely contributing to infection. We also sought to
determine if PKR, NIK or TAK1, known upstream kinases of IKK, contributed to NFB
activation. MEFs knocked out for functional PKR and cells transiently transfected with
dominant negative NIK or TAK1 constructs were characterized for NFB activation
following infection.
Differential roles of IKK and IKK in NFB activation
Normal, IKK-/- or IKK-/- MEFs were infected with wt virus and harvested at 8hpi or
treated with TNF for 15 min and harvested. Lysates were fractionated into either
cytoplasmic or nuclear partitions. Western blots were performed to assay for cellular
components of the NFB pathway and viral proteins (Fig 2.1). The phenotypes of the cell
lines were confirmed; both IKK and IKK were present in lysates from wild type MEFs,
while lysates from IKK-/- and IKK-/- MEFs lacked the respective IKK subunit. Detection
of the IKK subunits also served as a loading control for cytoplasmic extracts and a purity
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control for nuclear extracts. No IKK proteins were detected in the nuclear fractions (Data not
shown (DNS)). Similarly, PARP was used as our nuclear loading control and cytoplasmic
purity control and was also not detected in our cytoplasmic fractions (DNS). IB is the IKK
complex’s immediate down stream target and is degraded after IKK dependent
phosphorylation. IB was lost in wt and IKK-/- MEFS following both HSV infection and
TNF treatment. IKK-/- MEFs however did not lose IB. Translocation of p65 from the
cytoplasm to the nucleus followed a pattern similar to IB loss, as expected. Both wt and
IKK-/- MEF lysates had an increase in nuclear p65 upon HSV infection or TNF treatment.
Both also had increased total p65 following TNF treatment, possibly due to Sp1 dependent
activation of the p65 gene (109). One difference between these two cell lines was the portion
of p65 translocated. While wt MEFs translocated the majority of p65 to the nucleus, a
significant portion was still detectable in the cytoplasm. This was not the case for IKK-/-, 
where nearly all the p65 was translocated to the nucleus. This difference may be due to the
apparent smaller pool of total endogenous p65 in the IKK-/- cells. The IKK-/- MEFs had
some translocation of p65 to the nucleus following HSV infection or TNF treatment, though
much reduced in comparison to the proportions translocated in the other two cell lines, which
was consistent with the failure to turnover IB in the IKK-/- MEFs. These results suggest
that IKK is the dominant subunit responsible for phosphorylating IB and causing NFB
nuclear translocation following HSV infection and may indicate that some upstream
signaling components to IKK following infection are the same as those involved in TNF or
IL signaling, which also primarily signal through IKK.
Viral proteins were next assayed in these lysates. Both IE and E protein levels were
similar between all three cell types, as indicated by ICP27 (IE) and ICP8 (E). Both IKK-/- 
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and IKK-/- lines had reduced late protein abundance however. The true late gC was nearly
undetectable in both knockout lines, while the leaky late VP16 was reduced by roughly 5 fold
in both lines. The failure to produce late proteins suggests either a failure to properly
replicate the viral genome or disruption of viral late gene transactivation.
To assess NFB DNA binding ability, another marker of activation, the nuclear
lysates were subjected to electrophoretic mobility shift assay (EMSA). NFB complexes
were detected in all cell lines following either HSV infection or TNF treatment (Fig 2.2).
However, the level of a slower mobility complex in both IKK-/- and IKK-/- lines was
greatly reduced, slightly more so in the IKK-/- MEFs than the IKK-/- MEFs. Previously,
p65 and p50 were reported to form the dominant NFB dimer activated by HSV (11, 45, 74,
175). In order to determine if that was the case in our system, we used antibodies to
supershift the complexes. Antibody against E2F2 was used as an irrelevant control and did
not shift either complex. Antibody against p65 shifted the more abundant slower mobility
complex and antibody against p50 shifted both the abundant slow mobility complex and a
less abundant fast mobility complex. This pattern suggests that HSV primarily activates
p65/p50 heterdimers and to a lesser extent p50 homodimers in these MEFs. Some complexes
appeared to not be shifted following incubation with the p65 or p50 antibodies. The make up
of these complexes is unclear; possibly they are other NFB dimers or simply p65/50 or
p50/p50 dimers that were not bound by antibody.
As a final assessment of these MEFs, yield assays were performed. Monolayers were
infected and harvested at either 16 or 24 hpi. Virus was then titered on Vero monoloayers
(Table 2.1). Both knockout lines were deficient in viral yield, though the IKK-/- MEFs
much more so than the IKK-/- MEFs. The IKK-/- MEFs yielded 5.4 and 6.2 fold less virus
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at 16 and 24 hpi respectively than wt MEFs. The IKK-/- yields were 16.3 and 28.5 fold less
than wt. These results are consistent with the Western blot and EMSA data, showing a
greater contribution of IKK to NFB activation. However, the large difference in yield is
inconsistent with the similar deficiencies in late protein levels in the two cell lines and may
indicate further deficiencies of the IKK-/- cells.
NFB activation in PKR-/- MEFs
As active IKK is clearly necessary for NFB activation and viral replication, we
sought to determine what was leading to IKK activation. The double-stranded RNA
dependent protein kinase (PKR) is activated by a number of physiological stresses and can
cause NFB activation through Trafs, NIK and IKK (20). PKR is activated following HSV
infection, likely due to substantial symmetrical transcription following viral DNA replication
(175). One of the primary targets of PKR is eIF-2, which, once phosphorylated by PKR,
inhibits translation. Normally HSV antagonizes PKR via the late protein ICP34.5, which
promotes dephosphorylation of eIF-2. However, because PKR is not itself inhibited, it may
still activate NFB. To determine if this was the case we characterized HSV activation of
NFB in wt MEFs or MEFs lacking functional PKR (PKR+/+ and PKRo/o respectively).
To assess NFB activation following HSV infection of these cell lines, EMSA and
Western blotting were performed (Fig 2.3). NFB DNA binding was induced following
HSV infection or TNF treatment in the wild type cells. The p65/p50 and p50/p50 EMSA
complexes were again present, though in contrast to our previous results, HSV appeared to
induce p65/p50 and p50/p50 equally. This difference is likely caused by differential
transformation states of the wt cell lines. In the PKRo/o lines, there was p50/p50 complex
binding in untreated cells, indicating a constitutive activation of NFB. Both HSV infection
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and TNF treatment induced more NFB binding, though primarily of the p50/p50 complex.
TNF induction of p65/p50 complex was reduced in comparison to the wild type cell,
consistent with previous reports (27). HSV induction of the p65/p50 complex in PKRo/o cells
was unaffected, suggesting that PKR is not necessary for HSV activation of NFB. Western
blotting of protein equivalent samples supported this, as IB was lost following infection in
both cell types. The amount of ICP4 however, was greater in the PKRo/o cell line.
NFB activation in the presence of dominant negative TAK1 and NIK
TAK1 and NIK are important for NFB activation from a variety of signals. At the
time of this research, it was not know if either was activated following HSV infection,
though evidence for TAK1 activation has since be reported (93, 141). Given their prominent
roles in a diversity of NFB activation routes, we wished to ascertain whether they were
necessary for HSV NFB activation. To this end, we transiently transfected HEp-2 cells with
dominant negative constructs of either TAK1 or NIK and then infected them with HSV.
Cells were harvested at 8 hpi and Western blotting was performed (Fig 2.4). Increased levels
of TAK1 or NIK in their respective transected cells confirmed the expression of the dominant
negative constructs. The level of IB was comparable in the uninfected samples of all three
treatments. This result confirmed that the constructs were functionally inactive, as
overexpression of wild type TAK1 or NIK results in NFB activation (3, 109). In all cases,
IB was also lost following infection, suggesting that HSV either does not utilize either
TAK1 or NIK in activating NFB or uses redundant pathways to activate NFB. Also,
neither dominant negative construct inhibited NFB DNA binding activity as assayed by
EMSA (Gregory and Bachenheimer, unpublished observation).
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Significance of Results
HSV activation of NFB is essential for viral replication (64, 81-83, 150, 151). The
results here help further our understanding of how NFB is activated by HSV. Both IKK
and IKK appear to have distinct necessary functions for HSV NFB activation. PKR does
not appear to be necessary for NFB activation, though it is also activated by HSV infection.
Likewise, NIK and TAK1 activity is not necessary for NFB activation following infection.
The IKK subunits are both necessary for efficient replication though for different
reasons. Loss of IB and thus translocation of p65 to the nucleus were almost wholly
dependent upon IKK, while mostly independent of IKK. There was still some observable
p65 translocation and IB loss in the absence of IKK, likely due to compensating activity
of IKK. Both subunits are critical for NFB DNA binding, and thus likely for
transactivation ability. These roles are the same as those reported in the canonical NFB
pathway following TNF induction in MEFs. IKK was shown to be critical for IB
phosphorylation and degradation, and NFB translocation, DNA binding and gene
transactivation, while IKK had a minimal role in IB phosphorylation and degradation and
NFB degradation, but was also important for NFB DNA binding and gene transactivation
(149). Studies utilizing siRNA knockdown of the IKK subunits in HeLa cells also
demonstrated that IKK was the more important of the two subunits, but that the two IKKs
had a greater redundancy than the MEF studies indicated (109). Using siRNA knockdown
would also benefit our understanding of HSV NFB activation in more biologically relevant
human cell lines.
The IKK mediated NFB activation in MEFs is clearly relevant to HSV replication,
as failure of the activation causes up to 6 and 28 fold reductions in virus yield in IKK and
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IKK cells respectively, and appears to be important for late stages of infection. While there
was no deficiency in IE and E protein levels, late protein levels were greatly reduced. This
result is different from that seen previously following infection of IB-SR transfected C33
cells, where there was no observable change in viral proteins, including gC, despite a ~5 fold
reduction in yield and inhibition of IB loss and NFB DNA binding (50). However,
repetition of the DN-IB experiment in HEp-2 cells resulted in a similar decrease in gC,
suggesting that the difference in results is due to cell type differences (55). This result, along
with the results from the MEFs, indicates NFB serves an important function for viral DNA
replication and/or late gene expression.
While ICP27 is likely the viral activator of the sustained NFB activation, what other
viral or cellular factors mediate this activation has not yet been established fully (147). Our
results with the PKRo/o MEFs indicate that PKR is not necessary for HSV NFB activation,
however, this is the opposite of the conclusion reached by Taddeo et al., who reported that
NFB was not activated in this same cell line (136). In their report, they showed IB loss
was impaired and IKK kinase activity did not increase following infection in PKRo/o cells
compared to wild type cells. In contrast the results presented above show no difference in
IB loss and increase in NFB DNA binding activity. The difference in results with IB
might be explained by differences in HSV strains used; KOS1.1 vs F. It should be noted
however, that although they did not see an increase in IKK kinase activity following
infection in the PKRo/o cells, the basal level in the PKRo/o cells was greater than they
observed in the wt cells even after infection, suggesting a constitutive activation of the NFB
pathway in the PKR deficient cells. This is actually consistent with our observation that the
PKRo/o cells have p50 homodimer DNA binding activity in the absence of external stimuli.
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If the PKRo/o cells have an altered NFB pathway, any results regarding HSV NFB
activation are suspect. To more clearly determine if PKR is involved in HSV NFB
activation a different approach, such as siRNA or a specific PKR inhibitor, will have to be
used.
Our results also indicate that TAK1 and NIK are not necessary for HSV NFB
activation. Expression of dominant negative constructs of TAK1 or NIK did not interfere
with NFB activation by HSV as determined by IB loss. TAK1 is essential for NFB
activation initiated through a number of ligands and signaling pathways and operates by
directly activating IKK leading to IB degradation (27). Though there is some evidence
that TAK1 can be activated by ICP0, it is unclear whether this actually occurs during HSV
infection (87, 93, 141). Even if it is activated, it appears that HSV activates NFB primarily
by other mechanisms. Whether NIK is activated following HSV infection is unknown,
though it also appears to play no role in IB degradation following infection. NIK normally
targets IKK and is not necessarily critical for IB degradation. However, expression of a
dominant negative NIK antagonizes NFB activation by several pathways mediated by
Traf2, Traf6, IRAK and other factors (85, 137, 164). Because DN-NIK does not hinder HSV
NFB activation, it is likely that HSV mediates IKK activation through means normally not
utilized by the cell in response to cytokines. As such, discovering the immediate upstream
effectors of IKK might need to be done through assays of direct interaction following
infection, such as IPs.
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Figure 2.1
Figure 2.1. IKK is the primary kinase for IB loss and p65 nuclear translocation.
Fractionated lysates from wt, IKK-/- or IKK-/- MEFs harvested at 8 hpi were assayed for
cellular (A) or viral (B) proteins by Western blot. M, mock infected. H, infected with wt
HSV. T, treated with TNF for 15'.
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Figure 2.2
Figure 2.2. IKK and IKK are necessary for NFB DNA binding activity following
infection. A. Nuclear lysates from wt, IKK-/- or IKK-/- MEFs harvested at 8 hpi were
assayed for NFB DNA binding activity by EMSA. B. Nuclear lysates from wt MEFs
infected with HSV or treated with TNF were subjected to EMSA with antibodies against
E2F, p65 or p50. M, mock infected. T, treated with TNF for 15'. I, infected with wt HSV.
33
Table 2.1
Table 2.1. Virus yield from wt, IKK-/- and IKK-/- MEFs at 16 and 24 hpi. As per the
Materials and Methods in Chapter 1, cells and media from three independent experiments at
each time were collected and virus yields determined. Fold decrease is ratio of the yield
from the wt cells to the knockout cells.
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Figure 2.3
Figure 2.3. PKR is not required for NFB activation following HSV infection. Cells with or
without functional PKR were infected or treated with TNF. A. Nuclear lysates were
subjected to EMSA to detect NFB DNA binding. B. Whole cell lysates were subjected to
Western blotting to detect IB or ICP4. M, mock infected. I, infected with wt HSV.
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Figure 2.4
Figure 2.4. NIK and Tak1 are not necessary for NFB activation. HEp-2 cells were
transfected with plasmids expressing either dominant negative NIK or Tak1. After 16h the
cells were infected with wt HSV and harvested at 8 hpi. Lysates were assayed for IB loss
and NIK and Tak1 expression by Western blot. M, mock infected. K, infected with wt HSV.
CHAPTER 3
ACTIVATION OF THE DNA DSB RESPONSE FOLLOWING HSV INFECTION
Recently, many studies have begun to characterize the cellular the DSB response
following infection with HSV, the results of which were detailed in Chapter 1. For the
following part of my dissertation research I studied the DSB response in two biologically
relevant cell lines; hTERT immortalized human keratinocyes (HFKs) and normal human
lung fibroblasts (HELs). I initially characterized the status of the machinery most upstream
in the DSB response: the MRN complex and ATM. Upon discovering that the DSB response
was activated and that Mre11 was lost following infection, I further characterized the
requirements for each. The latter is the focus of Chapter 4. Here I will describe my findings
regarding the activation of the cellular DSB pathway.
The DSB response and Mre11 Loss Following HSV-1 Infection
Initially I sought to determine the status of the DSB response components following
HSV infection. HFKs (Fig 3.1) were infected with wild type HSV-1 at an MOI of 10 and
harvested at the indicated times. Lysates were analyzed by Western blot for viral and host
DSB response proteins. The IE protein ICP0 was detectable by 1 hour post infection (hpi)
and increased until 2 hpi, after which its accumulation remained unchanged. The early (E)
protein ICP8 was detectable by 2 hpi and reached a steady level by 4 hours. By 4 hpi, the
late (L) proteins VP16 and gC could be detected and increased in levels until at least 8 hpi.
This pattern suggests that viral DNA replication began between 2 and 4 hpi.
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Between 2 and 4 hpi I also observed activation of the DSB response proteins ATM
and Nbs1. Others have reported that such activation resulted from viral DNA replication
(85). Activated Chk2, however, was detected at 2 hpi. Chk2 activation preceding detectable
activation of other DSB response components following HSV-1 infection was also reported
by Lilley et al. and possibly indicates a limited amount of viral DNA replication at this
earlier time (85, 137, 164). I also observed loss of DNA-PKcs following infection in HFKs.
The loss began as early as 1hpi, though complete loss did not occur until after 2 hpi. Total
levels of Rad50 and Nbs1 did not significantly change following infection in HFKs, similar
to previous reports of other cell types (85, 137, 164). Essentially identical results were
obtained using HEL cells (DNS).
Mre11 levels were also reported to be unchanged following HSV-1 infection (85).
However, I observed a sharp decline in Mre11 levels between 2 and 4 hpi in HFKs and
HELs. This loss was slightly delayed when compared to DNA-PKcs loss. Due to the
temporal resolution of this experiment, I was unable to determine whether Mre11 loss
coincided with, or was preceded by, viral DNA replication. However, as Mre11 is necessary
for efficient viral DNA replication, the latter explanation is more likely (85, 137, 154, 164).
By immunofluorescence microscopy (IF), all three MRN components have been seen
localized at sites of HSV DNA replication (40, 116). To see how Mre11 and Nbs1 behaved
in our cell culture system, I infected either HFK or HEL at 0.01 MOI and fixed cells at
various times post infection up to 8h, then immuno-stained for either Mre11 or Nbs1, and
ICP8 and visualized by confocal microscopy (Fig 3.2A). By using a low MOI, I could
observe several early stages of infection as judged by ICP8 localization patterns (diffuse,
punctuate, small and large globular). Mre11 and Nbs1 were both localized diffusely
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throughout the nucleus with nucleolus exclusion in uninfected cells. Early during infection,
prior to detection of ICP8 or when ICP8 was diffuse, Mre11 and Nbs1 localization was
indistinguishable from uninfected cells (Fig 3.2 A&B). However, once ICP8 became
punctuate or globular, indicating localization to prereplicative sites and then replication
compartments, these proteins became enriched co-locally with ICP8, indicating their
presence at prereplicative sites and in replication compartments. Mre11 levels did not appear
to change during these times.
When I allowed the infection to proceed for 24h or 48h, I detected cells with bright
ICP8 staining throughout the nucleus but with little or no Mre11 staining (Fig 3.2C). In
contrast, Nbs1 staining persisted at these late times in cells with bright ICP8 staining.
Results from quantification of cellular staining patterns are shown in Table 3.1. These data
support the Western blot results in Figure 3.1 in suggesting Mre11 is lost following viral
DNA replication. The discrepancy in times at which Mre11 is lost is likely due to the
differences in MOI.
The requirement of de novo gene expression for the DSB response and Mre11 loss
Input HSV genomes are linear, but circularize shortly following infection, possibly
due to activity of the DSB response (85, 137, 164). As such, it would be expected that input
genomes are able to activate the DSB response. Also, HSV-1 infection inhibits host gene
expression, which would be expected to result in loss of unstable proteins as they turn over
and are no longer replenished. To test if input viral genomes activate the DSB response or if
Mre11 loss was due to instability, I infected HFKs or HELs in the presence or absence of
actinomycin D or cycloheximide to inhibit mRNA or protein synthesis respectively. Cells
were harvested at 16 hpi and the lysates analyzed by Western blot (Fig 3.3). Treatment with
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either drug prevented viral gene expression, as indicated by the lack of detectable ICP0.
Some gC was detected following drug treatment, likely from input virions. No Nbs1
activation was observed in the presence of either drug, indicating that input genomes are not
sufficient to cause detectable activation of the DSB response. Also, drug treatment did result
in roughly 50% reduction of Mre11 and Nbs1 levels, in both infected and uninfected cells.
However, HSV-1 reduced Mre11 levels to 10% of the untreated mock control, indicating that
loss was due to more than protein instability. These data also indicate that de novo viral gene
expression is needed for full Mre11 loss, consistent with the observed kinetics in Fig 3.1.
DSB response activation and Mre11 loss are dependent upon a late viral event
Our initial Western blot analysis (Fig. 3.1) suggested that the action of either early or
late viral functions were the effectors of DSB response activation and Mre11 loss. In order
to differentiate between early and late functions, I used various mutants to halt infection at
specific stages of gene expression. Mutants which fail to express either ICP4 (n12) or ICP27
(d27) are deficient in early and late gene expression. Infecting either HFKs or HELs with
these viruses did not result in DSB response activation or Mre11 loss (Fig 3.4). The amount
of ICP8 was reduced in n12 infection as expected, while ICP8 levels in d27 infection were
equivalent to wt. I did detect gC in both infections, though the minimal amounts are likely
the contribution of input virions. No ICP4 or ICP27 was detected in the lysates of cells
infected with their respective mutants, confirming their genotype. These data indicate that
DSB response activation and Mre11 loss require ICP4 and ICP27, as well as the expression
of early or late proteins dependent upon ICP4 and ICP27.
To allow E gene expression, but prevent L gene expression, I infected cells with
mutants deficient in ICP8 (d301) or viral DNA polymerase (HP66), or with wt virus in the
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presence of PAA, an inhibitor of the viral DNA polymerase. These conditions prevent viral
DNA replication and thus prevent true-late gene expression. HFKs or HELs infected with
the two mutants exhibited gC amounts above that seen after n12 infection, though reduced in
comparison to wt infection, while PAA treatment resulted in gC levels equivalent to that seen
with n12. IE and E gene expression was largely unaffected as demonstrated by ICP4, ICP0,
ICP27 and ICP8 levels. I did not observe Nbs1 activation under conditions which prevented
viral DNA replication, which is in contrast to previous reports that observed activation of
ATM and Nbs1 following HSV infection in the presence of PAA or acyclovir (another
inhibitor of viral DNA replication), though not following HP66 (pol-) infection (85). I did
not observe Mre11 loss under these conditions, suggesting that viral DNA replication and/or
L gene expression are necessary for its loss.
Importance of the DSB response for HSV replication
Previous reports on the importance of ATM in HSV infection are contradictory.
Lilley et al. reported that fibroblasts from Ataxia Telangiectasia (AT) patients and cells
treated with caffeine, which inhibits ATM activity, do not support efficient viral replication
(137). Shirata et al. also showed that AT fibroblasts were unable to support efficient viral
replication. However, using siRNA to knockdown ATM in 293T cells, they found no defect
in viral replication (58). To elucidate ATM’s importance to HSV replication and determine
if activation of ATM’s targets are necessary for Mre11 loss, HFKs were infected and either
left untreated or treated with caffeine or KU-55933 (ATMi), a specific inhibitor of ATM (85,
137, 164). Cells were harvested at 8 hpi for Western blotting or at 24 hpi for virus yield or
quantification of viral DNA by real time PCR (Fig 3.5 & Table 3.2). Western blot analysis
showed that while both caffeine and ATMi inhibited Nbs1 phosphorylation by ATM, ATMi
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was much more effective. Also, while caffeine greatly reduced gC levels, ATMi had no
effect. Neither prevented Mre11 loss, indicating that the loss was not dependent upon events
downstream of ATM in the DSB response. Caffeine treatment also resulted in a ~30%
reduction in viral genome copy number and a 10 to 38 fold reduction in virus yield while
ATMi treatment had no effect on genome copy number and only caused up to a 4 fold
reduction in yield. These results suggest that caffeine’s effects on HSV infection are largely
due to activities other than ATM inhibition, and that while ATM activation does contribute to
HSV replication, it is not essential.
Significance of results
The DSB response is activated following HSV infection. Input virus alone was
insufficient to trigger this activation and the activation required viral DNA replication and/or
late gene expression. While activation of this pathway did aid virus replication to some
degree, it was not necessary for replication. These observations are mostly in keeping with
those reported by others (137).
Most evidence suggests that activation of the DSB response is tied closely to viral
DNA replication. While input viral genomes are linear, and thus potentially recognizable by
the DSB response machinery, there is no evidence that they activate a large scale DSB
response. Infection with UV inactivated and wt virus in the presence of gene expression
inhibitors failed to cause detectable activation of the DSB response (85). Interference with
viral DNA replication does, however, hinder activation of the DSB response. Lilley et al.
reported that PAA treatment did inhibit activation of the DSB response following HSV
infection at low, but not high MOIs (137). Shirata et al. confirmed this result and also
demonstrated that acyclovir was able to interfere with the DSB response (164). Wilkinson
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and Weller also saw inhibition of the DSB response following PAA treatment and also saw
no activation by HP66 (pol-) infection (154). These reports, and that of Taylor and Knipe
(85, 137), also demonstrated that DSB components localize to sites of viral DNA replication,
and ATM and Nbs1 at these sites are activated. Taken together with my results, these reports
indicate that viral DNA replication triggers activation of the DSB response.
One discrepancy between our results and those of others is the effect of PAA on
inhibition of the DNA damage response. I used a relatively high MOI in my experiments,
which, according to Lilley et al. and Shirata et al. (164), should have been refractory to
PAA’s effects on Nbs1 activation. One likely reason that PAA, and also acyclovir, do not
always inhibit activation of the DSB response is that, depending upon the exact conditions,
these drugs allow some limited DNA replication. There were cell type and virus strain
differences between our study and others, which might account for different extents of viral
replication following drug treatment. Viral DNA replication was never directly assayed,
though I used gC as a surrogate and Wilkinson and Weller used IF to visualize replication
compartment formation (85, 137, 154, 164). In the future, a direct assay of viral DNA
replication, such as quantitative PCR, will be able to determine if it explains the different
results.
While the DSB response is likely activated by viral DNA replication, its importance
to viral replication is still not understood. Due to the localization of DSB machinery to
replication compartments, it has been proposed that the machinery helps facilitate viral DNA
replication (85). This hypothesis is supported by Lilley et al.’s results (137) showing that
cells from A-TLD or AT patients, thus deficient in Mre11 or ATM respectively, fail to
facilitate efficient viral replication with over a log reduction in yield. Cells treated with
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caffeine or expressing adenovirus E1B and E4orf6 proteins, which respectively are inhibited
for ATM activation or have the MRN complex degraded, also had over a log reduction in
yield. Mre11 deficient cells were also impaired for viral DNA replication. These results are
called into question by the report by Shirata et al. (137). They also noted a deficiency in viral
replication at the level of viral E protein in cells from AT or NBS (Nbs1 deficient) patients.
However, if the DSB response primarily plays a role in aiding viral DNA replication, it
should only cause reductions in L protein levels and not IE or E protein levels. They also
went on to show that siRNA knockdown of ATM in 293T cells had no effect on virus yield.
It is unclear what differences there might be in the cell types to account for the discrepant
results. It is possible that SV40 large T antigen is disrupting the normal DSB response in
293T cells, though Shirata et al. demonstrated that it was intact following irradiation (58).
In our cell system, it appears that the DSB response, at least at the level of ATM
activation, is not important for viral DNA replication and contributes only moderately to
virus replication. Because caffeine has targets other than ATM, I also used the newly
developed KU-55933 to specifically inhibit ATM activation (85, 152, 165, 171). While
caffeine did drastically reduce both viral yield and DNA replication, ATMi had no effect on
viral copy number and only moderately reduced virus yield. Thus, caffeine’s inhibitory
effects on virus replication are likely due to effects on targets other than ATM. How ATMi
affected viral replication is unclear, as there also seemed to be no defect in late gene
expression or viral genome copy number. One possibility is that failure to activate ATM
somehow interferes with proper assembly or egress of progeny virions. Another explanation
is that while viral DNA replication is able to produce equivalent genome copies with or
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without ATM activity, its absence results in defective genomes which are unable to
contribute to infectious progeny virus.
The results with ATM do not, however, provide insights into what role the MRN
complex, which is upstream of ATM, might play in HSV replication. Because recombination
is likely used by HSV to replicate its genome, and the MRN complex is normally necessary
for such mechanism, it is very likely that the MRN complex is necessary for viral DNA
replication, as suggested by the A-TLD and adenovirus protein expressing cells (85).
Because the results from the ATM deficient AT cells calls into question the results from A-
TLD cell lines and because of the possible multiple effects of adenovirus E1B and E4orf6
that cause MRN degradation, further studies are needed to elucidate the role of MRN in HSV
infection.
Another aspect of the DSB response in HSV infection is its implications for the
establishment of latency. Lilley et al. suggested that there may be a link between latency and
the DSB response, as neurons are deficient in the DSB response (146). They went on to
show that in vitro differentiated neurons infected with HSV do not activate the DSB response
and also do not form replication compartments. They suggested that the inability of neurons
to mount a DSB response causes a failure in viral replication leading to establishment of
latency. I find this unlikely however; as such defects would also likely equally impair
reactivation.
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Figure 3.1
Figure 3.1. The DSB response is activated and Mre11 lost following HSV infection. HFKs
were infected and harvested at the indicated times post infection. Whole cell lysates were
probed for cellular components of the DNA DSB response and viral proteins by Western
blot.
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Figure 3.2A
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Figure 3.2B
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Figure 3.2C
Figure 3.2. Mre11 and Nbs1 localize to sites of viral DNA replication. A & B. HFKs were
infected at an MOI of 0.01 and fixed at 2, 4, 6 & 8 hpi. IF was performed according to the
Materials and Methods in Chapter 1. Displayed cells are ordered to depict progression of
infection and do not represent particular time points. C. HFKs were infected as in A & B,
fixed at 24 or 48 hpi and subjected to IF.
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Table 3.1
Cells w/o Mre11 24hpi 48hpi
Uninfected 14.7%
(n=129)
22.7%
(n=79)
Infected 48.1%
(n=27)
70.8%
(n=24)
Table 3.1. Mre11 is lost at late times following HSV infection. Cells visualized by IF as
seen in Figure 3.2C were counted for the presence of Mre11 staining in conjunction with
ICP8 staining.
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Figure 3.3
Figure 3.3. Activation of the DSB response and Mre11 loss following infection require de
novo gene expression. HELs were infected in the presence or absence of Actinomycin D
(ActD) or Cycloheximide (CycloX). Whole cell lysates were assayed for components of the
MRN complex or viral proteins by Western blot. M, mock infected.
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Figure 3.4
Figure 3.4. The DSB response activation and Mre11 loss require viral DNA replication.
HFKs and HELs were infected with wt virus in the presence or absence of PAA or with the
mutants deficient in ICP8 (8-), polymerase (pol-), ICP4 (4-) or ICP27 (27-). Lysates were
assayed for cellular or viral proteins by Western blot. M, mock infected.
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Figure 3.5
Figure 3.5. ATM activation is not required for Mre11 loss, nor late gene expression. HELs
were infected in the presence or absence of caffeine (Caff) or KU-55933 (ATMi) and
harvested at 8 hpi. Whole cell lysates were assayed for cellular and viral proteins by Western
blot.
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Table 3.2
Table 3.2. ATM activity is not essential for viral replication. HELs were infected in the
presence or absence of Caffeine (Caff) or KU-55933 (ATMi) and harvested at 24 hpi.
Parrallel samples were assayed for viral yield or viral DNA copy as described in the
Materials and Methods in Chapter 1.
CHAPTER 4
CHARACTERIZATION OF MRE11 LOSS FOLLOWING HSV INFECTION
As presented in Chapter 3, Mre11 is lost following HSV infection of HFKs and
HELs. Adenovirus also causes loss of Mre11 in order to protect linear progeny genomes
from recognition by the MRN complex and subsequent repair, which would result in their
concatermizaration and/or circularization (18, 34, 89, 106). Though HSV DNA replication
mechanisms do not result in linear genome accumulation, the replicated DNA must be
processed into genome length units in order to be properly packaged into progeny virions. I
wondered if HSV might be also be inactivating the MRN complex by degrading Mre11 in
order to protect efficient processing and packaging of viral DNA. To test this model, I set
out to characterize the mechanism of Mre11 loss following infection. In Chapter 3 I
demonstrated that Mre11 loss requires de novo protein synthesis and is not caused by inherit
instability of the protein. I have also shown that Mre11 loss requires viral DNA replication
and occurs independent of ATM activity.
Mre11 loss is independent of ICP0, the proteasome and lysosome
ICP0 possesses E3 ubiquitin ligase activity and has been demonstrated to cause the
proteasomal dependent degradation of many cellular proteins; DNA-PKcs, CENP-A, CENP-
C, PMS and Sp100 (33). Though these targets of ICP0 are degraded early during infection,
ICP0 is present throughout the course of infection allowing for the possibility that it may
target Mre11 for degradation late during infection. To test whether ICP0 was necessary for
55
Mre11 loss, I infected HFKs with either wild type HSV-1 or the ICP0 mutant 7134 at various
MOIs. At 16 hpi, the cells were harvested and lysates analyzed by Western blot (Fig 4.1A).
At low MOI infections, ICP0 mutants are deficient in expression of other viral genes
(36). Here I saw no difference in gene expression between wt HSV-1 and 7134, regardless of
MOI, indicating that all the MOIs used were above the threshold of this deficiency. As
expected, 7134 failed to express ICP0 and thus did not cause DNA-PKcs degradation.
However, the absence of ICP0 had no discernable effect upon either activation of Nbs1 or
Mre11 loss. I observed similar results with HELs (DNS). These data indicate that ICP0 is
not required for Mre11 loss following HSV-1 infection.
The possibility remained that Mre11 was being degraded by the proteasome due to
the actions of other viral or cellular proteins. To determine if Mre11 loss was mediated by
the proteasome, I infected HFKs with wt HSV-1 in the presence or absence of MG132, an
inhibitor of the 26S proteasome. Cells were harvested at 8 hpi and lysates analyzed by
Western blot (Fig 4.1B). Treatment with MG132 protected DNA-PKcs from degradation and
had only a minor impact on viral protein levels. Activation of Nbs1 and viral protein levels
were slightly reduced by treatment with MG132. This was expected, since MG132 was
previously reported to hinder the progression of HSV infection (85, 137, 164). Mre11 levels
were minimally affected by MG132 treatment. While some Mre11 was retained following
MG132 treatment, comparison with DNA-PKcs protection clearly indicated that Mre11 loss
was largely due to mechanisms other than proteasomal degradation.
Because Mre11 did not appear to be lost through proteasomal degradation, I decided
to test if the lysosome was the cause of loss. HFKs were infected and after 1 hour, to allow
for absorption and release of capsids from endosomes, treated with NH4Cl. The cells were
56
harvested at 8 hpi and lysates subjected to Western blotting (Fig 4.1C). I observed no change
in Mre11 loss with either 10 or 20 mM NH4Cl, an inhibitor of lysosomal activity. These
concentrations were sufficient to prevent productive infection when present at the time of
infection (DNS). These data indicate that Mre11 loss is not mediated by the lysosome.
Mre11 loss is cell type specific
Others have reported that Mre11 is not lost following HSV infection of Vero, HeLa
or HFF cells (1, 8, 117, 126, 131, 133, 134). To determine if I could observe Mre11 loss in
cell types other than HFKs and HELs, I infected HeLa, HEp-2 and CV-1 cells with various
HSV strains. HeLa and HEp-2 cells were infected at MOIs of 5 or 10 respectively, with wild
type KOS or 17+, and ICP0 mutants 7134, d99 or d22, and harvested at 16 and 20 hpi (Fig
4.2 A & B). CV-1 cells were infected with KOS or 7134 at various MOIs and harvested at
20 hpi (Fig 4.2 C).
Western blotting of lysates from HeLa or HEp-2 cells showed infection with all
strains tested resulted in decreased Mre11 levels, while other cellular proteins were largely
unaffected. This was not the case with CV-1 cells. Initially I observed no change in Mre11
levels in whole cell lysates from CV-1 cells (DNS). To insure Mre11 was not being
inactivated by mislocalization, I prepared fractionated lysates from CV-1 cells infected at
various MOIs at 20 hpi. All the MRN components largely localized to the nucleus, with no
relocalization or reduction of levels. These results indicate that Mre11 loss is a cell type
dependent phenotype, though not a virus strain dependent phenotype.
Analysis of Late mutants for Mre11 loss
Because Mre11 loss did not occur in the absence of viral DNA replication and late
gene expression, I decided to assay viruses deficient in expression of various late genes for
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their ability to cause Mre11 loss. Because any benefit to HSV replication due to Mre11 loss
is likely to be due to preventing detection and subsequent repair of free DNA ends at late
times of infection, I felt it likely that Mre11 was being lost in order to protect the efficacy of
processing and packaging of progeny genomes, which results in generation of free DNA
ends. Thus, I chose to test mutants that have been characterized as deficient in proper
processing and packaging of progeny genomes. Mutant viruses individually deleted for UL6
(hr74), UL15 (hr81-1), UL17 (dUL17), UL25 (kUL25), UL28 (GCB) and UL32 (hr64) were
tested for Mre11 loss following infection (101). UL6 encodes the portal protein through
which DNA enters the capsid (2, 174). UL15 and UL28 gene products are components of the
terminase (97, 145). The UL25 gene product is necessary for stabilizing encapsidated DNA
and late stages of capsid maturation (75, 153). UL17 and UL32 expression is necessary for
correct localization of preformed capsids to sites of DNA packaging (30).
I infected HFKs (Fig. 4.3A) and HELs (DNS) with these mutants and harvested at
8hpi to test for Mre11 loss. I noted that the UL15 and UL17 mutants consistently, and UL6
mutant occasionally, showed less Mre11 loss than wt virus, as seen in Fig. 4.3A. However,
further analysis of the lysates revealed reduced levels of selected viral proteins. This defect
has been previously seen for these mutants and contributed to a high complementation index
when titers were determined on complimenting cell lines (personal communication, S. Weller
& J. Baines). These mutants also exhibited reduced activation of Nbs1, indicating inefficient
viral DNA replication. As such I could not determine whether the failure to cause Mre11
loss was due to the specific loss of the viral genes or due to the general replication defect.
In order to overcome this defect in general viral fitness for the viral mutants hr81-1,
hr74 and dUL17, I repeated infections at an MOI of 200 (Fig. 4.3B). At this MOI, viral
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protein levels in the mutant infected cells were equal to or in excess of that of wt virus at an
MOI of 20, and Nbs1 activation was also equivalent to wt infected cells. However, under
these conditions I also no longer saw any defect in Mre11 loss. This result would indicate
that UL15, UL6 and UL17 products are unnecessary for Mre11 loss.
Another late function that could affect Mre11 loss is the viral protease encoded by
UL26, which conceivably could directly target Mre11. To determine if UL26 was necessary
for Mre11 loss, I infected HFK cells with UL26dZ, a mutant with a deletion of the entire
UL26 orf, or UL26H61E, a point mutant disabling the protealytic activity of the viral
protease (Fig. 4.3C). At an MOI of 20, these mutants had no defect in Mre11 loss or viral
protein accumulation. This result suggests that the viral protease does not contribute to loss
of Mre11.
Camptothecin causes Mre11 loss
Though none of the late mutants I tested were defective in Mre11 loss in the end, I
did make an interesting observation that Mre11 loss was occasionally observable despite
absence of detectable late proteins (DNS). This observation led us to consider the possibility
that viral DNA replication, rather than a viral encoded late function, was the trigger of Mre11
loss. As viral DNA replication is the trigger for activation of the DSB response, I considered
the possibility that activation of the DSB response could lead to Mre11 degradation, perhaps
as part of a negative feedback loop. However, in Chapter 3 I demonstrated that inhibition of
ATM and thus the DSB response downstream of ATM did not affect Mre11 loss. Mre11 is
upstream of ATM, and thus it would still be possible that engagement of DNA ends by the
MRN complex would be sufficient to cause Mre11 loss.
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If MRN detection and engagement of DSBs were sufficient to cause Mre11 loss, I
would expect this to occur outside the context of HSV infection. To test if this was the case,
I treated cells with camptothecin (CPT), which results in the generation of free DNA ends
and activation of the DSB response in S-phase cells due to topoisomerase I inhibition.
Because CPT primarily functions in S-phase, I serum starved confluent HEL cultures and
then released them by passaging in media with serum. After allowing 20 hours for the cells
to re-enter the cell cycle, which has previously been shown to result in an enriched S-phase
population, cells were treated with CPT and/or ActD (85, 137, 164). ActD was used to
control for differences in protein level due to differential cell growth. After 4 hours
treatment cells were harvested and lysates subjected to Western blotting (Fig 4.4). Rad50
and tubulin levels were reduced equally in all cells treated with ActD, with or without CPT,
in comparison to untreated cells. ActD treatment also resulted in reduced Mre11 levels,
though combined ActD and CPT treatment caused further reduction. CPT treatment alone
resulted in a further reduction of all protein levels compared to ActD treatment. A possible
cause for this might be a greater induction of apoptosis in these cells, though no
cytopathology was observable (DNS).
Though the reduction in Mre11 following CPT was insignificant compared to that
observed following HSV infection, this result does indicate that activation of the DSB
response, or perhaps certain general cellular stresses, can cause Mre11 turnover. I suspect
that the loss of Mre11 was less significant due to the fact that CPT treatment most greatly
affects cells in S-phase. While my conditions should enrich for an S-phase population, many
cells were likely still in G1/G0 or perhaps had progressed beyond S-phase by 20 hours after
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release from serum starvation. As such, a portion of the cells were unaffected by CPT
treatment, thus reducing the observable loss.
Significance of Results
Mre11 loss following HSV infection would be expected to inhibit the ability of the
cellular DSB response machinery to recocognize and respond to DSBs. How this loss might
affect HSV replication, if it does at all, is unclear. Here, I have shown that Mre11 loss
following HSV infection is a late event that is dependent upon viral DNA replication and
perhaps late gene expression. Unlike many other cellular proteins that are lost following
HSV infection, Mre11 loss is not caused by ICP0 activity, nor does it depend upon the
proteasome or lysosome, though it is possible that NH4Cl does not fully inhibit the
protealytic activity of lysosomes. As these general degradation mechanisms appear not to be
involved in Mre11 loss, the actions of specific proteases is left as the most plausible
explanation for the loss. Another possibility is that Mre11 is being displaced from the MRN
complex, resulting in its instability and degradation. This is unlikely however, as it would
still depend upon Mre11 being degraded by the proteasome or lysosome.
Others have not reported that Mre11 is lost following infection, though their systems
utilized different cell types and/or virus strains (20, 85, 137, 164). In my hands, I found that
Mre11 loss was dependent upon cell type, though not virus strain. The basis for the
differences between the cell types is unknown, though notably the one cell type in which I
observed no loss of Mre11 at all was a non-human primate derived line, whereas all others
tested were of human origin. Further experiments may determine if this is a human specific
phenotype.
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My results suggest that either viral DNA replication or the function of late genes
trigger Mre11 loss following HSV infection. While I have shown a number of late gene
functions to be unnecessary for Mre11 loss, it remains possible that there is a functional
redundancy amongst those I tested or that a function I have not tested is responsible for
Mre11 loss. I expect this not to be the case however, as Mre11 loss is observable in the
absence of late protein expression, which leaves viral DNA replication as the likely trigger
for loss. To further confirm this, late genes could be expressed from a cosmid library to
determine if any are sufficient to cause Mre11 loss.
If viral DNA replication does trigger Mre11 loss, the mechanisms of how this occurs
is unclear. It is possible that viral DNA replication allows an IE or E protein to either
directly or indirectly target Mre11, leading to Mre11’s degradation. However, I have already
demonstrated that the most likely candidate, ICP0, is not necessary for Mre11 loss. No other
IE or E proteins have characterized functions that would suggest they would be involved in
protein loss. Another possible mechanism would involve a cellular protein being triggered
by viral DNA replication to cause Mre11 loss. As it is known that viral DNA replication
does trigger some cellular stress pathways, such as the DSB response and PKR, this is a
reasonable possibility (85).
If activation of such stress pathways does lead to Mre11 loss, I would expect their
activation to lead to Mre11 loss out of the context of infection. I found this was indeed the
case for the DSB response induced by CPT treatment. This result may indicate that the
activation of the MRN complex by viral DNA replication leads to Mre11 turnover.
However, as Mre11 loss still occured when ATM activation was inhibited, the loss would not
be the result of effectors in the DSB response pathway downstream of ATM. If Mre11 loss
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is simply a by-product of DSB response activation, it may be that loss does not contribute to
viral replication. Given that Mre11 is likely important for viral DNA replication, its loss may
in fact be detrimental (48, 114). Even so, the observed loss of Mre11 following CPT
treatment may represent a novel negative regulatory mechanism for the DSB response.
Further experiments are needed to identify the exact mechanism of Mre11 loss and
determine if loss following HSV infection and CPT treatment are in fact the same. Use of
specific and broad range protease inhibitors might identify the relevant protease and thus also
allow the significance, if any, of Mre11 loss to viral infection to be determined. Otherwise,
tagging of Mre11 and either pull down experiments or live cell microscopy tracking may
provide clues to the fate of Mre11 through identification of interacting proteins or
observation of aberrant localization.
Figure 4.1A
63
Figure 4.1. Mre11 loss does not require ICP0 or the activities of the proteasome or
lysosome. A. HFKs were infected with wt or a ICP0 deficient virus at the indicated MOIs
and harvested at 8 hpi. Whole cell lysates were assayed for cellular and viral proteins by
Western blot. B & C HFKs were infected with wt virus and were overlayed with media with
or without MG132 or NH4Cl at the indicated concentrations at 1 hpi. Lysates were assayed
by Western blot for cellular and viral proteins. M, mock infected. H, infected with wt HSV.
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Figure 4.1B
Figure 4.1C
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Figure 4.2A
Figure 4.2B
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Figure 4.2C
Figure 4.2. Mre11 loss is cell type dependent. HeLa (A), HEp-2 (B) and CV-1 (C) cells
were infected with the indicated wt or ICP0 deficient viruses at the indicated MOIs and
harvested at the indicated times. A & B. Whole cell lysates were probed for cellular and
viral proteins by Western blot. C. Fractionated lysates were likewise probed.
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Figure 4.3
Figure 4.3. Processing and packaging mutants cause Mre11 loss. HFKs were infected with
wt or the indicated mutants characterized for defective processing and packaging of viral
DNA (A & B) or the viral encoded protease (C). Mutant viruses were used at an MOI of 20
(A) or 200 (B). Lysates were analyzed for cellular and viral proteins by Western blot.
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Figure 4.4
Figure 4.4. Camptothecin treatment causes Mre11 loss. HELs were growth arrested by
contact inhibition and serum starvation. 20 hours following release from arrest by replating
in fresh media, cells were treated with camptothecin (CPT) or actinomycin D (ActD) for 4
hours. Whole cell lysates were assayed for Rad50, Mre11 and tubulin by Western blot.
CHAPTER 5
CONCLUSIONS
Viruses are efficient pathogens that are absolutely dependent upon a host cell to
complete their life cycle. To facilitate viral replication, host cell machinery is co-opted by
the virus to carry out necessary tasks in replication. In this dissertation I have characterized
two instances in which HSV interacts with host cell signaling machinery to benefit its own
replication. First, I have demonstrated the independent importance of the two kinase
components to the IKK complex, IKK and IKK, in the activation of the NFB pathway
following HSV infection. Second, I have demonstrated activation of the DSB response and
the loss of Mre11, a component of the DSB response, following HSV infection. Here I will
discuss the relevance of these findings to our knowledge of HSV life cycle and consider
future research in these areas.
NFB activation
I have shown that the second sustained NFB activation following HSV infection is
dependent upon both IKK and IKK. IKK was necessary for NFB DNA binding activity,
and thus any transactivation or transrepression activity NFB may normally have during
HSV infection. IKK was necessary for IBa degradation and thus p65/p50 nuclear
translocation. It is also possible that IKK plays a further role in controlling DNA binding
ability or transactivation ability, though it was not possible to assay for these activities due to
the upstream defects in the pathway.
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IKK has been shown to be important for NFB binding to a subset of its responsive
promoters, likely due to phosphorylating p65 and or p50 (113). IKK can also function as a
derepressor by targeting transcriptional repressors SMRT and HDAC3 for removal from
NFB target genes and by phosphorylating histone H3 (123). To determine if IKK has
similar functions during HSV infection several experiments need to be performed. If IKK
does directly target p65 or p50 during infection, this could be revealed by comparision of
phosphorylated residues detected by Western blot of lysates from cells with or without
functional IKK. Also, cells expressing p65 with alanine substitutions mutations at sites
targeted by IKK could be infected to determine if they replicate the IKK null phenotype
seen in Chapter 2. Conversely, glutamic acid substitutions, which can mimic
phosphorylation at these residues, could be used to assay complementation of NFB
activation and HSV replication defects in IKK-/- cells.
Similarly, Western blotting for phosphorylated sites on repressors, such as SMRT and
HDAC3, and H3 from infected cells with or without IKK could determine if IKK
functions as a derepressor following HSV infection. Also, chromatin immunoprecipitation
(ChIP) could be performed to analyze the differential make up of the chromatin structures at
HSV dependent NFB bound sites in cells with or without IKK. This experiment would
also require identifying sites, other than the ICP0 promoter, that are bound by NFB
following infection. The VP16 promoter is the only other site in the HSV genome with
identified putative NFB sites (113). Other sites could be identified by performing ChIP
with antibodies against p65, blunt cloning the released DNA fragments and sequencing them.
This method would identify any bound DNA not already known or not identifiable by
scanning for putative NFB binding sites in the HSV or cellular genomes.
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Determining if IKK also has a role in activation of p65/p50 by phosphorylation
following infection will be more difficult, as the defect in IB turnover and p65
translocation must be bypassed to determine if any such phosphorylations are important for
DNA binding or transactivation. Some p65 translocation is seen in IKK-/- cells, and thus it
may be possible to directly detect phosphorylation sites by Western blot. Sites that are
targeted in wt, but not IKK-/-, cells would determine which residues, if any, are targeted by
IKK following HSV infection. Alanine replacements could again be tested to determine if
any of the IKK targeted sites are important. Glutamic acid replacement would be useful if
IB degradation can be affected without IKK activation and activation of other pathways
that potentially lead to p65 or p50 phosphorylation.
The observation that IKK-/- cells had up to a 28 fold reduction in yield and IKK-/- 
cells had only up to a 6 fold reduction while both failed to activate NFB and allow for
substantial late gene expression suggests that IKK has additional roles outside of NFB
activation. In addition to the NFB subunits, IKK has been shown to phosphorylate Bcl10,
IRS1, Dok1, 14-3-3 and FOXO3a (109). Currently there are no reports of activation of these
targets following infection. Assaying for such activations could potentially reveal additional
roles for IKK in HSV infection.
Though IKK is the primary activator of NFB following infection, the upstream
effector is still unknown. I tested two upstream factors known to activate NFB primarily
through IKK, PKR and Tak1, as well as Nik, which normally signals through IKK, for
their importance in HSV NFB activation. PKR was tested using deficient cell lines while
dominant negative constructs of Tak1 and NIK were used to test for their contribution. None
were necessary for NFB activation following HSV infection. Whether HSV utilizes
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existing cellular pathways that activate IKK or simply encodes its own activating function
remains to be determined. Current evidence suggests that IKK activation may involve both
of the above.
Both ICP4 and ICP27 contribute to NFB activation following HSV infection (55).
More recent studies by Hargett et al. (54, 55) indicate that ICP27 is necessary and sufficient
for NFB activation. They also demonstrated that p38 and JNK signaling, which ICP27 also
triggers, contribute to HSV NFB activation. That the ICP27 mutant dLeu was capable of
activating p38 and JNK, but was deficient in NFB activation, indicates both that ICP27
activation of p38 and JNK is not sufficient for NFB activation, and that it either utilizes an
as yet undescribed pathway to activate NFB, or perhaps directly contributes to NFB
activation (4, 49, 50). Further experiments characterizing ICP27 mutants and their physically
interacting proteins and other signaling pathways will lead to a more complete understanding
of HSV NFB activation.
The other important aspect of NFB signaling during HSV infection is its role in
virus infection. Currently there is evidence that NFB activates the ICP0 gene and prevents
apoptosis following HSV infection (123). How NFB affects apoptosis prevention during
infection and what other roles it may play are not yet known. Because the promoter of VP16
also contains putative NFB binding sites, it is likely that NFB also activates VP16
expression (72). It is also possible that NFB binds other unidentified sites in the HSV
genome and activates other genes. Further studies utilizing ChIP may reveal such sites in
relevant cell types, as discussed above.
NFB anti-apoptotic activity is well characterized following TNF induction (5, 65).
NFB activates expression of a number of anti-apoptotic genes, such as those encoding IAPs,
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Bcl2 family members, TRAF2 & 5 and others. Though it is not known how HSV affects
transcription of all of these genes, Bcl-2 and XIAP are upregulated and play a role in
preventing apoptosis following infection (85, 137, 164). It is not known whether this
upregulation is dependent upon NFB. Assaying mRNA levels of Bcl-2 and XIAP, as well
as other NFB dependent anti-apoptotic genes, following infection of cells unable to activate
NFB, such as the IKK knockout MEFs or cells transfected with DN-IB, will establish
whether they are in fact activated by NFB. Further studies utilizing cells knocked out or
down for these upregulated genes will confirm the role for Bcl-2 and XIAP in preventing
apoptosis following infection and determine if any other factors play a similar role.
DBS response activation
I have shown that HSV activates the DSB response following infection, dependent
upon viral DNA replication, in accordance with reports from others (85). The significance of
this observation is not entirely clear. While immunofluorescence and immunoprecipitation
data clearly demonstrate interactions between the DSB machinery and viral DNA replication,
its role remains unknown. The most likely explanation is that the DSB machinery aids in
facilitating later stage recombination dependent viral DNA replication. This might explain
my observation that inactivation of ATM did not greatly affect viral genome copy number or
virus yield, as ATM is not essential for recombination, though it does contribute to its
efficacy.
Mre11 is upstream of ATM and is necessary for recombination. Fibroblasts deficient
for Mre11 (A-TLD derived) or cells where Mre11 is degraded (expressing adenovirus EIB
and E4Orf6) are defective in facilitating virus replication and, at least in the case of the
former, DNA replication (19). WRN is another protein involved in recombination (154).
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Cell lines deficient for WRN also have been shown to be defective in supporting viral
replication and HSV specific recombination (85). These results strongly suggest that HSV
requires DSB and recombination machinery to replicate its DNA. Further studies could be
performed to directly assay the resulting replicated DNA structures under conditions where
host recombination machinery is perturbed. Knock out cell lines and siRNA mediated
knockdown of other components of the DSB response would further our understanding of the
exact mechanisms that are used in HSV DNA replication. It may also be possible to use
electron microscopy of HSV DNA at various stages of replication to directly visualize the
replication mechanisms.
Mre11 loss
Because Mre11 appears to be necessary for efficient viral replication, it is curious that
Mre11 is lost following infection . However, because Mre11 loss also only occurs following
initiation of DNA replication, it may be that it has served its utility by the time of loss.
Another possibility is that Mre11 loss may limit the extent of viral DNA replication. A third
non-mutually exclusive possibility, which I originally hypothesized upon observation of
Mre11 loss, is that the loss is beneficial to HSV because it prevents interference with
processing and packaging of progeny genomes. Packaged genomes are linear and could be
acted upon by the DSB response machinery if the free DNA ends were accessible. Though
the exact mechanism of packaging is not known, it is thought to be similar to phage
packaging and thus packaged genomes are not likely to be accessible to cellular machinery.
Nonetheless, packaging would still result in the unpackaged viral DNA having free DNA
ends that would be accessible to the host machinery. Processing of these ends by the MRN
complex could then be detrimental to further packaging.
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To test these models, a method of inhibiting Mre11 loss without interfering with
Mre11 activity would have to be developed. While I have done much to advance our
understanding of what triggers Mre11 loss following HSV infection, I have not discovered a
method of preventing Mre11 loss without also preventing DNA replication where it likely
functions to the benefit of the virus. It is clear that unlike the case of most host proteins lost
following infection, ICP0 is not responsible for Mre11 loss. Even more curious, neither the
proteasome nor the lysosome are effectors of Mre11 loss. While it remains possible that a
function encoded by a late gene is responsible for the loss, I have not been able to identify a
late protein that is necessary for Mre11 loss. As Mre11 loss was observable in the absence of
late gene expression, I hypothesized that activation of the DSB response by DNA replication
triggers the loss. Credence for this model is gained from the observation that camptothecin
(CPT), which also activates the DSB response, causes Mre11 loss. Inhibition of ATM
activation does not prevent Mre11 loss, indicating that the upstream engagement of the MRN
complex is sufficient for Mre11 loss absent any signaling downstream of ATM.
Further study is required to confirm that DSB damage can trigger Mre11 turnover.
Cell lines expressiong mutant forms of Mre11 or Rad50 which are either unable to bind and
process DNA or unable to engage Nbs1 could be used to determine if such activities are
necessary for Mre11 loss after HSV infection. Also, direct visualization of live cells with
florescence-tagged Mre11 may enable us to track the fate of Mre11 following the induction
of DSBs caused by CPT or other damaging agents. Along with confirming the trigger for
Mre11 loss, the mechanism of loss must still be determined. As the proteasome and
lysosome have been eliminated as mechanisms for Mre11 loss, only specific proteases are
left as likely effectors of Mre11 loss.
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I have determined that UL26, the HSV encoded protease, is not required for Mre11
loss, leaving either an undiscovered viral protease or a cellular protease as the effecter of
Mre11 loss. Because Mre11 loss appears to be a normal cellular response to DSB stimulus,
Mre11 is more likely to be targeted by a cellular protease. Broad range and specific protease
inhibitors could be used to determine what type of protease is involved. Inhibitory
conditions might also allow for the protease to be pulled down with Mre11 by IP, and thus
directly identified. Identification of the protease responsible for Mre11 would finally allow
determination of whether Mre11 loss is beneficial, neutral or harmful to HSV replication.
Effects of inhibition of the protease could be assayed first by yield assay, and then by
assaying effects on viral DNA replication, processing and packaging. Because of potential
secondary effects of protease inhibition, Mre11 proteins resistant to protease cleavage could
be designed to directly assay for the importance of Mre11 loss, provided such changes do not
also interfere with MRN activity.
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